

Platelet transfusion in neonatal intensive care units of 22 European countries: a prospective observational study



Nina A. M. Houben,^{a,b,*} Enrico Lopriore,^b Karin Fijnvandraat,^{c,d} Camila Caram-Deelder,^b Marta Aguar Carrascosa,^e Alain Beuchée,^f Kristin Brække,^g Francesco Cardona,^h Anne Debeer,ⁱ Sara Domingues,^j Stefano Ghirardello,^k Ruza Grizelj,^l Emina Hadžimuratović,^m Christian Heiring,ⁿ Jana Lozar Krivec,^{o,p} Jan Malý,^q Katarina Matasova,^r Carmel Maria Moore,^{s,t} Tobias Muehlbacher,^u Miklos Szabó,^v Tomasz Szczapa,^w Gabriela Zaharie,^x Justine de Jager,^b Nora Johanna Reibel-Georgi,^y Helen V. New,^z Simon J. Stanworth,^{z,aa} Emöke Deschmann,^{ab} Charles C. Roehr,^{ac,ad,ae} Christof Dame,^y Saskia le Cessie,^b Johanna van der Bom,^b and Suzanne Fustolo-Gunnink,^{a,b,c} for the INSPIRE Study Group

^aSanquin Research, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands

^bLeiden University Medical Centre, Leiden, the Netherlands

^cAmsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Meibergdreef 9, Amsterdam, the Netherlands

^dSanquin Research, Department of Molecular Cellular Hemostasis, Amsterdam, the Netherlands

^eLa Fe University Hospital, Valencia, Spain

^fCHU de Rennes, Rennes, France

^gOslo University Hospital, Oslo, Norway

^hMedical University Vienna, Vienna, Austria

ⁱUZ Leuven, Leuven, Belgium

^jCentro Materno-Infantil do Norte - Unidade Local de Saúde de Santo António, Porto, Portugal

^kFondazione IRCCS Policlinico San Matteo, Pavia, Italy

^lUniversity Hospital Centre Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia

^mUniversity Medical Centre Sarajevo, Sarajevo, Bosnia and Herzegovina

ⁿDepartment of Neonatal and Paediatric Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

^oUniversity of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

^pUniversity Medical Centre Ljubljana, Ljubljana, Slovenia

^qUniversity Hospital Hradec Králové, Hradec Králové, Czech Republic

^rJessenius Faculty of Medicine, University Hospital Martin, Martin, Slovakia

^sUniversity College Dublin, Dublin, Ireland

^tNational Maternity Hospital, Dublin, Ireland

^uUniversity Hospital Zurich, Zurich, Switzerland

^vDepartment of Neonatology Semmelweis University, Budapest, Hungary

^wII Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland

^xUniversity of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania

^yCharité - Universitätsmedizin Berlin, Berlin, Germany

^zNHS Blood and Transplant, London, United Kingdom

^{aa}University of Oxford, Oxford, United Kingdom

^{ab}Karolinska Institute, Stockholm, Sweden

^{ac}National Perinatal Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom

^{ad}Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom

^{ae}Women's and Children's Division, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom

Summary

Background Platelet transfusions are given to preterm infants with severe thrombocytopenia aiming to prevent haemorrhage. The PlaNeT2/MATISSE trial revealed higher rates of mortality and/or major bleeding in preterm infants receiving prophylactic platelet transfusions at a platelet count threshold of $50 \times 10^9/L$ compared to $25 \times 10^9/L$. The extent to which this evidence has been incorporated into clinical practice is unknown, thus we aimed to describe current neonatal platelet transfusion practices in Europe.

Methods We performed a prospective observational study in 64 neonatal intensive care units across 22 European countries between September 2022 and August 2023. Outcome measures included observed transfusion prevalence rates (per country and overall, pooled using a random effects Poisson model), expected rates based on patient-mix (per country, estimated using logistic regression), cumulative incidence of receiving a transfusion by day 28 (with

The Lancet Regional
Health - Europe
2024;47: 101086

Published Online 10
October 2024
<https://doi.org/10.1016/j.lanepe.2024.101086>

*Corresponding author. Nina Houben. Sanquin Blood Supply Foundation / Leiden University Medical Center, Plesmanlaan 125, 1066 CX Amsterdam / Albinusdreef 2, Leiden 2333 ZA, the Netherlands.

E-mail address: n.a.m.houben@lumc.nl (N.A.M. Houben).

death and discharge considered as competing events), transfusion indications, volumes and infusion rates, platelet count triggers and increment, and adverse effects.

Findings We included 1143 preterm infants, of whom 71 (6.2%, [71/1143]) collectively received 217 transfusions. Overall observed prevalence rate was 0.3 platelet transfusion days per 100 admission days. By day 28, 8.3% (95% CI: 5.5–11.1) of infants received a transfusion. Most transfusions were indicated for threshold (74.2%, [161/217]). Pre-transfusion platelet counts were above $25 \times 10^9/L$ in 33.1% [53/160] of these transfusions. There was significant variability in volume and duration.

Interpretation The restrictive threshold of $25 \times 10^9/L$ is being integrated into clinical practice. Research is needed to explore existing variation and generate evidence for various aspects including optimal volumes and infusion rates.

Funding Sanquin, EBA, and ESPR.

Copyright © 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Keywords: Platelet transfusion; Thrombocytopenia; Preterm infants; Neonatology; Neonatal intensive care unit; Europe; Epidemiology

Research in context

Evidence before this study

We searched Pubmed for randomized trials comparing platelet transfusion thresholds in preterm infants from database inception to May 1st 2024 without language restrictions. The search included the terms “neonate”, “randomized trial”, “platelet transfusion”, “platelet count” and their synonyms. Three trials were identified, with the PlaNeT2/MATISSE trial being the most extensive conducted to date. This trial, published in 2019, reported higher rates of mortality and/or major bleeding in preterm infants receiving prophylactic platelet transfusions at a liberal threshold of $50 \times 10^9/L$ compared to a restrictive threshold of $25 \times 10^9/L$. Despite the need for further research to replicate this finding and unravel the mechanisms underlying the potential harm, these results support restrictive platelet transfusion strategies in preterm infants. We also performed a similar search for international studies describing platelet transfusion practices in preterm infants across Europe, using the terms “neonate”, “Europe”, “platelet transfusion” and their synonyms. Two international surveys were identified, of which the most recent survey conducted in 2020 reported that 47–57% of European NICUs (depending on gestational age) used

thresholds higher than $25 \times 10^9/L$ for preterm infants without clinical bleeding, despite trial evidence.

Added value of this study

This is the first prospective study describing platelet transfusion practices across 22 European countries. We found that 8.3% of very preterm infants received at least one platelet transfusion during the first 28 days after birth. The primary indication given for most transfusions was the platelet count threshold. Around one third of transfusions based on platelet count threshold were given above the restrictive PlaNeT2/MATISSE transfusion threshold of $25 \times 10^9/L$. We found substantial differences in platelet transfusion volumes, durations, and infusion rates across Europe.

Implications of all the available evidence

The restrictive threshold of $25 \times 10^9/L$ as evaluated in the PlaNeT2/MATISSE trial is increasingly becoming part of managing thrombocytopenia in preterm infants in Europe. Our results highlight ongoing practice variation. Research gaps were identified for areas such as optimal volumes and infusion rates.

Introduction

Platelet transfusions are administered to preterm infants with severe thrombocytopenia (platelet count below $50 \times 10^9/L$) to reduce the risk of major haemorrhage. The PlaNeT2/MATISSE randomized controlled trial on platelet transfusion thresholds, published in 2019, revealed potential harm associated with platelet transfusion.¹ There were higher rates of mortality and/or major bleeding in preterm infants with a gestational age (GA) below 34 weeks receiving prophylactic platelet

transfusions at a liberal threshold of $50 \times 10^9/L$ compared to a restrictive threshold of $25 \times 10^9/L$. Although further research is needed to confirm these findings and to understand the mechanisms underlying the potential harm, this indication of potential harm, combined with the lack of evidence for benefit of liberal transfusion strategies, may justify restrictive platelet transfusion strategies in preterm infants. A European survey conducted in the following year reported that 47–57% of NICUs used thresholds higher than

$25 \times 10^9/L$ for non-bleeding very preterm and extremely preterm infants respectively.² It is not known to what extent the restrictive threshold has since been adopted in clinical practice. Additionally, there is lack of robust evidence on neonatal transfusion thresholds for specific indications such as invasive procedures, and on other aspects of platelet transfusion practice such as optimal transfusion volumes and rates. There is a need for high quality epidemiological data on neonatal transfusion practices to explore variation in practice, to identify research priorities, and to translate into future studies and implementation projects. We therefore conducted a prospective observational study describing the platelet transfusion prevalence and incidence, primary indications for transfusion, platelet count prior to transfusion, volume, and infusion rate of transfusion, platelet count transfusion increment, and transfusion related adverse effects across 64 NICUs in 22 European countries.

Methods

Study design and participants

This study was part of the International Neonatal Transfusion Point Prevalence (INSPIRE) study, an international, multicentre, prospective, observational cohort study describing red blood cell (RBC), platelet and plasma transfusion practices in European NICUs.

The Medical Research Ethics Committee of the Leiden University Medical Centre (Leiden, The Netherlands) approved the study protocol (G21.207), followed by national or regional ethics committees in the participating countries. National coordinating neonatologists guided the recruitment process of participating centres in their respective countries. Together we selected a representative sample of NICUs to invite, considering the size of centres, their academic and non-academic status, and surgical versus non-surgical units, aiming to accurately reflect the diversity of centres within their country. The number of centres invited per country was proportional to country population size, aiming to have larger countries contribute more centres than smaller countries, and aiming for at least two participating centres per country. Approximately 77 centres across 22 European countries were invited, all tertiary level NICUs providing continuous life support and comprehensive care for infants born below 32 weeks gestation. Study conduct complied with the Declaration of Helsinki and the General Data Protection Regulation. A parent advisory board, in partnership with the European Foundation for the Care of the Newborn Infant (EFCNI), provided feedback in all stages of the study. The study protocol included all infants with a GA at birth of less than 32 weeks who were admitted to a participating NICU during the study period. Of note, we restricted our study population to infants born before 32 weeks, instead of 34 weeks as applied in the PlaNeT2/MATISSE trial, as very preterm infants <32 weeks were

most likely to receive blood transfusions and were at higher risk for severe thrombocytopenia. Parents and guardians provided consent after prior information if required by national or regional legislation. We registered the study protocol ([Supplement 1](#)) in the ISRCTN registry (registration number ISRCTN17267090).

Procedures

We collected data between September 2022 and August 2023 over a six week study period in the respective centres. We included infants at NICU admission, date of consent, or start of study period, whichever occurred last. Study follow-up continued until the first of the following time points: death, discharge, or end of study period. We defined a transfusion event as the administration of a platelet transfusion. For each transfusion event, we collected the primary indication for transfusion, platelet count closest before and after transfusion (within 24 h pre- and post-transfusion), transfusion volume and duration, and possible transfusion associated adverse effects. Furthermore, we recorded occurrence of major bleeding, culture-positive sepsis, necrotizing enterocolitis (NEC), invasive mechanical ventilation, and surgery (definitions in [Supplementary Table S1](#)). We collected all study data using a certified electronic Castor database that complies with ICH E6 Good Clinical Practice standards.

Outcomes

Main study outcome measures included the platelet transfusion day prevalence rate, the patient-mix adjusted transfusion day prevalence rate, and the cumulative incidence of receiving at least one platelet transfusion during the first 28 postnatal days of life adjusted for competing risks of death and discharge. In the cumulative incidence analysis, we only included patients whose follow-up started at their date of birth. We defined a platelet transfusion day as any admission day in the study period on which the patient received at least one platelet transfusion. We defined the platelet transfusion day prevalence rate as the number of platelet transfusion days per 100 NICU admission days. We used this definition to account for the varying lengths of study follow-up between patients which is inherent to the dynamic cohort study design.

Additional study outcomes included primary indications for transfusion, volume, duration, and infusion rate of transfusion, platelet count prior to transfusion, platelet count transfusion increment, and transfusion related adverse effects.

Statistical analyses

We formulated a statistical analysis plan prior to conducting the analyses ([Supplement 2](#)). Patient and centre characteristics are presented as median (interquartile range (IQR)) or frequency (%). To compute the observed prevalence rate, we conducted a meta-analysis to pool

centre prevalence rates into subgroup estimates by country, and then into an overall estimate.

For this, we employed a random effects Poisson model using function 'metarate' from package 'meta' (R statistical software, version 4.1.17, R Core Team, Vienna, Austria, 2021), given that we expected considerable variability between countries.³

We calculated patient-mix adjusted prevalence rates per country through a three-step approach. First, we fitted a logistic regression model with transfusion day (yes/no) as dependent variable and eleven clinical covariables as independent variables (sex assigned at birth, GA at birth, birth weight, congenital anomalies, small for gestational age (SGA), major bleeding, necrotizing enterocolitis (NEC), culture-positive sepsis, mechanical ventilation, surgical procedure, postnatal day). This model estimated the probability of receiving at least one platelet transfusion per infant per day. We averaged these predictions to obtain the expected prevalence rate per country. Thereafter, we divided observed transfusion prevalence rates per country by expected prevalence rates per country. Lastly, we multiplied these country observed/expected ratios with the overall observed prevalence rate to obtain patient-mix adjusted prevalence rates.

Additionally, we calculated the cumulative incidence of receiving at least one platelet transfusion during the first 28 days of life, with death and discharge considered as competing events. We only included infants who were followed up from birth in this analysis, using the 'cuminc' function from package 'cmprsk' (nonparametric Aalen-Johansen estimate, R statistical software).

We computed infusion rate of transfusion (mL/kg/hour) by dividing transfusion volume (mL/kg) by transfusion duration (hours). We compared platelet counts prior to transfusion with the liberal ($50 \times 10^9/L$) and restrictive ($25 \times 10^9/L$) threshold as evaluated in the PlaNet2/MATISSE trial.¹ We calculated transfusion increment by subtracting platelet count closest after transfusion from platelet count closest before transfusion (all within 24 h pre- and post-transfusion).

We conducted the analysis for the additional study outcome measures using STATA statistical Software (version 16.1, Texas, USA). We made figures using GraphPad Prism (Version 9.3.1, California, USA). We adhered to the STROBE reporting guideline for observational studies.

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

Patients and centres

We included 1143 patients in 64 centres across 22 European countries, with a median study follow-up per

patient of 20 days (IQR: 10–35), totaling 24,978 patient days. The median number of patients per centre was 17 (IQR: 11–25). Patients had a median GA at birth of 28 + 2 weeks (IQR: 26 + 2 to 30 + 2 weeks) and a median birth weight of 1030 g (IQR: 780–1350 g). Mortality during study follow-up was 6.3% (72/1143; 6.3%), at a median postnatal age of 8 days (IQR: 4–18). During study follow-up, 37.5% (428/1143) of preterm infants were discharged, at a median postnatal age of 42 days (IQR: 20–68). Re-admission to the NICU after initial discharge during the study period was 1.6% (18/1143). Patient and centre characteristics are provided in [Supplementary Tables S3 and S4](#), respectively.

Platelet transfusion

In total, 71 patients (71/1,143, 6.2%) received one or more platelet transfusions, collectively receiving 217 transfusions, with a median of two platelet transfusions per transfused infant (IQR: 1–4). The overall platelet transfusion day prevalence rate was 0.3 platelet transfusion days per 100 admission days (95% CI: 0.2–0.5), corresponding to 3 platelet transfusion days per 1000 admission days. Observed prevalence rates and expected prevalence rates based on patient-mix are presented in [Fig. 1](#). Observed/expected prevalence rate ratios per country ranged from 0.1 to 1.9, indicating that some countries transfuse less (ratio below 1.0) or more (ratio above 1.0) than expected based on case mix ([Supplementary Table S4](#)). The proportion of infants that received at least one platelet transfusion by day 7 of life was 5.5% (95% CI: 3.3–7.6), and 8.3% by day 28 of life (95% CI: 5.5–11.1), with death and discharge considered as competing events and based on 468 out of 1143 (40.9%) infants that were followed from birth ([Fig. 2](#)).

Transfusion indication

The primary indication for most transfusions was platelet count threshold (161/217; 74.2%; [Fig. 3](#)). Other primary transfusions indications included active bleeding (22/217, 10.1%), surgical procedures (14/217; 6.5%), prevention of major bleeding (based on other factors besides platelet count; 8/217; 3.7%), critically ill conditions (such as NEC and sepsis; 7/217; 3.2%), lumbar puncture (1/217; 0.5%), urinary catheter placement (1/217; 0.5%), low molecular weight heparin treatment for inferior vena caval thrombosis (1/217; 0.5%), nonactive bleeding (1/217; 0.5%), and petechiae (1/217; 0.5%).

Transfusion volume, duration and infusion rate

For the 161 transfusions given based on threshold, transfusion volumes ranged from 5 to 25 mL/kg, durations ranged from less than 15 min to 3 h, and infusion rates ranged from below 10 to >40 mL/kg/hour ([Fig. 4A](#)). The majority of these transfusions had volumes of 15 mL/kg (104/161; 64.6%), followed by




Fig. 1: Overall observed platelet transfusion day prevalence rates, and observed and expected (based on patient mix) prevalence rates per country. Observed prevalence rates were calculated using random effects Poisson models to pool transfusion day prevalence rates from the individual centres into country subgroup estimates and subsequently to derive the overall estimate. Confidence intervals were in part determined by the sample size per country as well as the practice variation between centres within one country. Upper limit confidence intervals of Hungary and United Kingdom were outside of axis limits. Expected prevalence rates as predicted based on patient-mix using a logistic regression model which included the following variables: sex assigned at birth, GA at birth, birth weight, congenital anomalies, SGA, major bleeding, NEC, sepsis, mechanical ventilation, surgical procedure, postnatal day.




Fig. 2: Cumulative incidence of receiving at least one platelet transfusion during the first 28 postnatal days of life. Adjusted for the competing risks of death and discharge without platelet transfusion (presented as cumulative incidence, with corresponding 95% confidence intervals). Figure is based on 468 out of 1143 (40.9%) infants that were followed from birth. The number at risk and the number of events per postnatal day are available in [Supplementary Table S5](#).




Fig. 3: Primary indications for 217 platelet transfusions. Indications for transfusion were platelet count threshold (161/217, 74.2%), active bleeding (22/217, 10.1%), surgical procedures (14/217, 6.5%), prevention of major bleeding (based on other factors besides platelet count; 8/217, 3.7%), critically ill conditions (such as NEC and sepsis; 7/217, 3.2%), and other indications (5/217, 2.3%). Other indications included lumbar puncture, urinary catheter placement, low molecular heparin weight treatment for inferior vena cava thrombosis, nonactive bleeding, and petechiae.

20 mL/kg (30/161; 18.6%). The most common durations were 30 min (77/161; 47.8%) and 1 h (49/161; 30.4%). The most common infusion rates were 10–20 mL/kg/hour (46/161; 28.6%) and 30–40 mL/kg/hour (44/161; 27.3%). Data on transfusions given for active bleeding, surgery, prevention of major bleeding, critically ill conditions or any other indication are provided in Fig. 4B.

Platelet count prior to transfusion

Platelet counts within 24 h pre-transfusion were available for 211 out of 217 (97.2%) transfusions. This included 160 out of 161 (99.3%) transfusions given based on threshold (Fig. 5). The median platelet count prior to transfusion given based on threshold was $18 \times 10^9/L$ (IQR: 12–31). Compared to the thresholds used for non-bleeding infants in PlaNeT2/MATISSE trial, 107 (107/160; 66.9%) of these transfusion had a platelet count below the restrictive threshold of $25 \times 10^9/L$, 45 (45/160; 28.1%) between the restrictive and below the liberal threshold (25 – $50 \times 10^9/L$), and 8 (8/160; 5.0%) were given at or above the liberal threshold of $50 \times 10^9/L$. Median platelet counts prior to transfusion given for indications other than threshold ranged from $43 \times 10^9/L$ to $65 \times 10^9/L$. Transfusion indications stratified by pre-transfusion platelet counts below $25 \times 10^9/L$ or equal to or above $25 \times 10^9/L$ are available in Supplementary Table S6.

Transfusion increment

Platelet count increment data were available in 131 out of 161 (81.4%) transfusions given based on threshold. The median increment was $20 \times 10^9/L$ per transfusion (IQR: 4–52) (Supplementary Fig. S1). We also plotted

the association between platelet count increment and transfusion volume (Supplementary Fig. S1).

Transfusion associated adverse effects

No adverse effects potentially linked to a preceding platelet transfusion were reported during the study period.

Discussion

To the best of our knowledge, this is the first prospective study describing platelet transfusion practices in preterm infants across Europe. We found varying platelet transfusions rates across the 22 participating countries, with one in three platelet transfusions indicated for platelet counts above the restrictive PlaNeT2/MATISSE threshold of $25 \times 10^9/L$ and widely varying transfusion volumes and durations.

Several national studies have previously assessed platelet transfusion practices following publication of the PlaNeT2/MATISSE trial, reporting proportions ranging from 5.0 to 11.9% of preterm infants receiving at least one platelet transfusion, similar to the 8.3% we observed.^{4–8}

The majority of transfusions (161/217; 74.2%) were indicated primarily based on platelet count threshold. These transfusions are likely to have been given prophylactically with the aim of reducing the risk of bleeding, although their effectiveness in preventing bleeding in preterm infants has never been conclusively established.^{9,10} Furthermore, there is no straightforward causal link between the degree of thrombocytopenia and bleeding risk, and it is known that bleeding is a multi-factorial process influenced by various other factors in




Fig. 4: a. Transfusion volume, duration and infusion rate of 161 transfusions given based on threshold. Transfusion volumes were 5 mL/kg or less in 1.9% (3/161), 10 mL/kg in 13.0% (21/161), 15 mL/kg in 64.6% (104/161), 20 mL/kg in 18.6% (30/161), and 25 mL/kg in 1.9% (3/161). Transfusion durations were 30 min or less in 47.8% (77/161), 1 h in 30.4% (49/161), 1.5 h in 3.1% (5/161), 2 h in 13.7% (22/161), 2.5 h in 0.6% (1/161), and 3 h in 4.4% (7/161). Colors reflect most common infusion rate within each dot, infusion rates of individual transfusions within one dot may vary as infusion rates were calculated using unrounded transfusion volumes and durations. Percentages in figure represent the proportion of transfusions indicated for threshold given at this volume and duration. b. Transfusion volume, duration and infusion rate of transfusions given for active bleeding, surgery, prevention of major bleeding, critically ill conditions or any other indication. Volume and duration were available in 50 out of 56 transfusions (89.3%). Colors reflect most common infusion rate within each dot, infusion rates of individual transfusions within one dot may vary as infusion rates were calculated using unrounded transfusion volumes and durations. Percentages in figure represent the proportion of transfusions indicated for active bleeding, surgery, prevention of major bleeding, critically ill conditions or any other indication given at this volume and duration.

addition to platelet count.^{9,11–14} This complexity is evident from the fact that not all infants with severe thrombocytopenia bleed, and not all infants with major bleeding have severe thrombocytopenia.¹⁵

Two thirds of the transfusions primarily based on platelet count were administered when counts were below $25 \times 10^9/L$ (66.9%), suggesting that the restrictive

threshold found beneficial in the PlaNeT2/MATISSE trial is being integrated into European neonatal intensive care. In a 2020 survey, 47–57% of European NICU still reported using thresholds above this restrictive threshold for very preterm as well as extremely preterm infants.² Another retrospective study including both term and preterm infants in the United States,




Fig. 5: Platelet count prior to transfusion. Platelet counts prior to transfusion were available in 211 out of 217 transfusions (97.2%). The dotted lines represent the liberal transfusion threshold of $50 \times 10^9/\text{L}$ and restrictive transfusion threshold of $25 \times 10^9/\text{L}$ as evaluated in the PlaNeT2/MATISSE trial. The middle line of each box denotes the median, the ends of the box denote the 25th to 75th percentile, the whiskers denote the minimum to maximum range. Platelet count prior to transfusion given for active bleeding ($n = 1$ transfusion) and surgical procedure ($n = 3$ transfusions) outside axis limits, respectively.

published in 2021, reported a median platelet count of $71 \times 10^9/\text{L}$ prior to prophylactic and therapeutic platelet transfusions combined.¹⁶ In our study, the median platelet count prior to platelet transfusion indicated by platelet was $18 \times 10^9/\text{L}$, which would be consistent with a threshold of $25 \times 10^9/\text{L}$ being used in practice. Additionally, some centres may apply even more restrictive thresholds such as $20 \times 10^9/\text{L}$ for non-bleeding infants.² Without further evidence, there remains clinical equipoise in terms of safety and effectiveness of transfusion thresholds below $25 \times 10^9/\text{L}$ for non-bleeding infants.

While our findings suggest progress in the integration of a restrictive prophylactic platelet transfusion threshold in Europe, more than 30% of transfusions were still given for platelet counts above $25 \times 10^9/\text{L}$, some even exceeding the liberal threshold of $50 \times 10^9/\text{L}$. This suggests that the restrictive threshold has not been adopted in clinical practice by all centres. The exact reasons for this ongoing threshold variation across practices are not well known. Possibly, dissemination of PlaNeT2/MATISSE trial results may be incomplete or guidelines have not been updated following publication.

Moreover, clinicians may have deviated from applied restrictive thresholds due to various reasons. Notably, only 37% of infants in the PlaNeT2/MATISSE trial were enrolled before or on day 5 of life, which may have led some clinicians to be hesitant to adhere to the restrictive threshold during these first days of life.^{1,17} For this specific reason, a new RCT is currently in preparation in the US to compare restrictive versus liberal transfusion thresholds for extremely preterm infants during the first week of life and beyond (Neonatal Platelet Transfusion Threshold Trial (NeoPlaTT), NIH RePORTER #1UG3HL173303-01). Alternatively, clinicians may have anticipated a subsequent decline in platelet count, prompting an early transfusion decision above the restrictive threshold level. However, given the evidence for harmful short- and long-term effects of higher platelet transfusion thresholds, the use of prophylactic platelet transfusions for platelet counts above $25 \times 10^9/\text{L}$, in the absence of active bleeding or surgical procedures, should be discouraged.^{1,18} Of note, we only recorded the primary indication for transfusion, so secondary reasons other than platelet count may also have

contributed to the transfusion decision. As platelet count alone may not be a reliable predictor of bleeding, this may have impacted clinical decision-making in various scenarios.

Notably, approximately 10% of transfusions were given therapeutically to preterm infants experiencing active bleeding, aiming to improve primary hemostasis by increasing the platelet count. We currently lack robust evidence concerning optimal transfusion thresholds for active bleeding and other indications such as surgical or invasive procedures. We observed marked variability in platelet counts prior to transfusion given for active bleeding as well as surgical procedures, consistent with this limited evidence base. The design of further studies in these areas of therapeutic practice is challenging, but given the potential risks for harm with platelet transfusions, a better pathophysiological understanding is needed.

We found that in 20.5% (33/161) of platelet transfusions indicated for low platelet count, volumes of 20 mL/kg or higher were administered. In this context, it should be noted that neonatal platelet transfusions are most frequently given prophylactically to euvolemic infants without clinical bleeding. In comparison, adults usually receive around 200–300 mL platelet transfusions, equivalent to approximately 5 mL/kg or less. The most common duration of platelet transfusions for those transfused based on platelet count was 30 min (77/161, 47.8%), resulting in almost half of transfusions given at infusion rates of either 30 or 40 mL/kg/hour. Platelet transfusions in adult patients are also commonly administered over 30 min, probably for historical considerations including minimising time without platelet agitation, although this is a relatively short period compared to accepted platelet transportation non-agitation limits.¹⁹ However, due to the relatively higher volumes administered to infants in relation to body weight, these short durations result in much higher infusion rates per kg body weight for preterm infants.²⁰ The short transfusion durations may be beneficial for patients with clinical bleeding by achieving higher platelet counts more rapidly. However, preterm infants have a fragile cerebral germinal matrix and rapid volume expansion could theoretically harm this by disrupting cerebral or abdominal blood flow, potentially contributing to the development of intraventricular haemorrhage or NEC.^{12,21} In infants, RBC transfusions are usually given over much longer durations to mitigate potential adverse effects of rapid transfusion administration. It is unclear why similar precautions are not applied with platelet transfusions in preterm infants. Only one small randomized study has compared platelet transfusion durations of 30 min and 2 h in preterm infants in relation to platelet count increments, showing that longer transfusion durations yielded similar platelet transfusion increments.²² Large comparative studies are urgently needed to evaluate the efficacy and tolerance of

transfusion volumes and infusion rates in non-bleeding infants, and to unify current practices. The use of hyper concentrated platelet transfusions could be beneficial for preterm infants by mitigating these fluctuations caused by high volumes.^{23,24} A single participating centre in our study used hyper concentrated platelet components.²⁵ Further research should clarify whether smaller volumes are safer and effective.

We did not document any immediate adverse effects potentially associated with platelet transfusion. Platelet transfusions are reported to contribute more frequently to transfusion related adverse effects in adult and paediatric patients compared to RBC transfusions.²⁶ Preterm infants are inherently susceptible to potential transfusion-related adverse effects given their immaturity. In preterm infants, severe thrombocytopenia is often associated with platelet consumptive and platelet activating diseases such as sepsis or NEC (possibly one of the reasons for the relatively low platelet increments shown in this study).²⁷ This complexity may hamper the recognition of platelet transfusion-related adverse effects, in particular if infants receive multiple interventions at the same time. Thus, it seems likely that adverse effects are underrecognized and underreported. Apart from potential short-term harm associated with platelet transfusion, there is also evidence for long-term harm. The PlaNeT2/MATISSE trial reported higher rates of the secondary outcome bronchopulmonary dysplasia (BPD) in the $50 \times 10^9/\text{L}$ transfusion threshold arm as well as short-term harm (major bleeding and/or mortality day 28 of life).¹ Platelets also play a crucial role in host immunity and release various immune response modifiers, including those that are found only in adult platelets and can contribute to the development of BPD.^{28–31} There is evidence that platelet transfusions can provoke inflammatory responses or amplify existing inflammation in preterm infants, a potential mechanism leading to long-term harm.^{32–36}

Study limitations include the relatively small number of infants included per country, partly due to the six week study period per centre, limiting the interpretation of results at the national level. We did not collect information on the component specifications or platelet counts of the platelet components transfused, known to influence transfusion platelet count increment. Additionally, we did not assess the use of alternative hemostatic therapies such as tranexamic acid and coagulation factor concentrates.

In conclusion, we found the restrictive PlaNeT2/MATISSE transfusion threshold of $25 \times 10^9/\text{L}$ is being integrated into clinical practice. Yet, one third of transfusions based on platelet count threshold as primary indication were given above this threshold of $25 \times 10^9/\text{L}$. Our results highlight the ongoing practice variation and

underline the need for further evidence on various aspects of platelet transfusion practices including optimal volumes and infusion rates.

Contributors

NH, EL, KF, HVN, SJS, ED, CCR, CD, JB, SFG have designed the study. SFG obtained funding. NH, EL, KF, CCD, MAC, AB, KB, FC, AD, SD, SG, RG, EH, CH, JLK, JM, KM, CMM, TM, MS, TS, GZ, NRG, ED, CCR, CD, SC, JB, SFG contributed to the data collection and/or helped interpret the data. NH and JJ coordinated the study. EL, KF, CCD, JB, SFG supervised the project. NH, CCD, MAC, AB, KB, FC, AD, SD, SG, RG, EH, CH, JLK, JM, KM, CMM, TM, MS, TS, GZ, NRG, ED, CCR, CD provided administrative, technical and/or material support. NH, CCD, SC, JB wrote the statistical analysis plan and performed the statistical analysis. NH and CCD have directly accessed and verified the underlying data reported in the manuscript. NH, EL, KF, SFG wrote the first draft of the manuscript. All authors critically reviewed the draft manuscript and approved the final version prior to submission.

Data sharing statement

No consent was obtained for further data sharing. External applications for data access will therefore only be taken into consideration after the prior written consent of all participating centres.

Declaration of interests

CH and TM have received compensation from Sanquin Blood Supply Foundation. JM has received compensation from Sanquin Blood Supply Foundation, research grants from Cooperatio and Personmed, and consulting fees from Danone, Nestlé, Baxter, and Chiesi. All other authors declare no competing interests.

Acknowledgements

SFG has received research grants from Sanquin Blood Supply Foundation (PPOC21-08/L2588, RES/00264), the European Blood Alliance (EBA Grant Agreement 2021–02), and the European Society for Paediatric Research (ESPR Post-Doc Research Grant 2020). The INSPIRE Study Group members (non-author collaborators) appear in [Supplement 3](#). We would like to thank Oliver Karam, Marianne Nellis, Martha Sola-Visner, Amy Keir and Naomi L.C. Luban for their advice as members of the study advisory board. The study was funded by Sanquin Blood Supply Foundation (PPOC21-08/L2588, RES/00264), the European Blood Alliance (EBA Grant Agreement 2021–02) and the European Society for Paediatric Research (ESPR Post-Doc Research Grant 2020). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: Funding for this project has been provided in full or in part through an Agreement with the European Blood Alliance (EBA). The contents of this document do not necessarily reflect the views and policies of the EBA, nor does mention of trade names or commercial products constitute endorsement or recommendation of use.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.lanepe.2024.101086>.

References

- Curley A, Stanworth SJ, Willoughby K, et al. Randomized trial of platelet-transfusion thresholds in neonates. *N Engl J Med*. 2019;380(3):242–251.
- Scrivens A, Reibel NJ, Heeger L, et al. Survey of transfusion practices in preterm infants in Europe. *Arch Dis Child Fetal Neonatal Ed*. 2023;108(4):360–366.
- Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. *Stat Med*. 2010;29(29):3046–3067.
- Davenport PE, Chan Yuen J, Briere J, Feldman HA, Sola-Visner MC, Leeman KT. Implementation of a neonatal platelet transfusion guideline to reduce non-indicated transfusions using a quality improvement framework. *J Perinatol*. 2021;41(6):1487–1494.
- Borges JP, dos Santos AM, da Cunha DH, Mimica AF, Guinsburg R, Kopelman BI. Restrictive guideline reduces platelet count thresholds for transfusions in very low birth weight preterm infants. *Vox Sang*. 2013;104(3):207–213.
- Zabeida A, Chartrand L, Lacroix J, Villeneuve A. Platelet transfusion practice pattern before and after implementation of a local restrictive transfusion protocol in a neonatal intensive care unit. *Transfusion*. 2023;63(1):134–142.
- Bahr TM, Christensen TR, Henry E, et al. Platelet transfusions in a multi-neonatal intensive care unit health care organization before and after publication of the PlaNet-2 clinical trial. *J Pediatr*. 2023;257:113388.
- Heeger LE, Houben NAM, Caram-Deelder C, Fustolo-Gunnink SF, van der Bom JG, Lopriore E. Impact of restrictive platelet transfusion strategies on transfusion rates: a cohort study in very preterm infants. *Transfusion*. 2024;64(8):1421–1427.
- Sparger KA, Assmann SF, Granger S, et al. Platelet transfusion practices among very-low-birth-weight infants. *JAMA Pediatr*. 2016;170(7):687–694.
- Fustolo-Gunnink SF, Huisman EJ, van der Bom JG, et al. Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates? A systematic review. *Blood Rev*. 2019;36:1–9.
- Baer VL, Lambert DK, Henry E, Christensen RD. Severe thrombocytopenia in the NICU. *Pediatrics*. 2009;124(6):e1095–e1100.
- Ballabh P. Intraventricular hemorrhage in premature infants: mechanism of disease. *Pediatr Res*. 2010;67(1):1–8.
- von Lindern JS, van den Bruele T, Lopriore E, Walther FJ. Thrombocytopenia in neonates and the risk of intraventricular hemorrhage: a retrospective cohort study. *BMC Pediatr*. 2011;11:16.
- Muthukumar P, Venkatesh V, Curley A, et al. Severe thrombocytopenia and patterns of bleeding in neonates: results from a prospective observational study and implications for use of platelet transfusions. *Transfus Med*. 2012;22(5):338–343.
- Stanworth SJ, Clarke P, Watts T, et al. Prospective, observational study of outcomes in neonates with severe thrombocytopenia. *Pediatrics*. 2009;124(5):e826–e834.
- Patel RM, Hendrickson JE, Nellis ME, et al. Variation in neonatal transfusion practice. *J Pediatr*. 2021;235:92–99.e4.
- van der Staaij H, Stanworth SJ, Fustolo-Gunnink SF. Prophylactic platelet transfusions: why less is more. *Clin Perinatol*. 2023;50(4):775–792.
- Moore CM, D'Amore A, Fustolo-Gunnink S, et al. Two-year outcomes following a randomised platelet transfusion trial in preterm infants. *Arch Dis Child Fetal Neonatal Ed*. 2023;108(5):452–457.
- Thomas S. Platelets: handle with care. *Transfus Med*. 2016;26(5):330–338.
- Sahota G, Munir T, Chang C. Platelet transfusions. *BMJ*. 2011;343:d6847.
- Kalteren WS, Bos AF, Bergman KA, van Oeveren W, Hulscher JBF, Kooi EMW. The short-term effects of RBC transfusions on intestinal injury in preterm infants. *Pediatr Res*. 2023;93(5):1307–1313.
- Dannaway DC, Noori S. A randomized trial of platelet transfusions over 30 vs 120 minutes: is there an effect on post-transfusion platelet counts? *J Perinatol*. 2013;33(9):703–706.
- Moore CM, Curley AE. Neonatal platelet transfusions: starting again. *Transfus Med Rev*. 2021;35(3):29–35.
- Bassan H. Intracranial hemorrhage in the preterm infant: understanding it, preventing it. *Clin Perinatol*. 2009;36(4):737–762.
- Honohan A, van't Ende E, Hulzebos C, et al. Posttransfusion platelet increments after different platelet products in neonates: a retrospective cohort study. *Transfusion*. 2013;53(12):3100–3109.
- European Commission Directorate-General for Health and Food Safety. *Summary of the 2022 annual reporting of serious adverse reactions and events for blood and blood components*. 2023.
- Strauss RG. Platelet transfusions in neonates: questions and answers. *Expert Rev Hematol*. 2010;3(1):7–9.
- Davenport P, Sola-Visner M. Platelet transfusions in neonates: beyond hemostasis. *Arterioscler Thromb Vasc Biol*. 2023;43(6):886–888.
- McFadyen JD, Kaplan ZS. Platelets are not just for clots. *Transfus Med Rev*. 2015;29(2):110–119.

-
- 30 Waubert de Puiseau M, Sciesielski LK, Meyer O, et al. Pooling, room temperature, and extended storage time increase the release of adult-specific biologic response modifiers in platelet concentrates: a hidden transfusion risk for neonates? *Transfusion*. 2020;60(8):1828–1836.
 - 31 Bahr TM, Snow GL, Christensen TR, et al. Can red blood cell and platelet transfusions have a pathogenic role in bronchopulmonary dysplasia? *J Pediatr*. 2024;265:113836.
 - 32 Moore CM, O'Reilly D, McCallion N, Curley AE. Changes in inflammatory proteins following platelet transfusion in a neonatal population. *Pediatr Res*. 2023;94(6):1973–1977.
 - 33 Davenport P, Sola-Visner M. Hemostatic challenges in neonates. *Front Pediatr*. 2021;9:627715.
 - 34 O'Reilly D, Murphy CA, Drew R, et al. Platelets in pediatric and neonatal sepsis: novel mediators of the inflammatory cascade. *Pediatr Res*. 2022;91(2):359–367.
 - 35 Maurya P, Ture SK, Li C, et al. Transfusion of adult, but not neonatal, platelets promotes monocyte trafficking in neonatal mice. *Arterioscler Thromb Vasc Biol*. 2023;43(6):873–885.
 - 36 Davenport P, Soule-Albridge E, Sola-Visner M. Hemostatic and immunologic effects of platelet transfusions in neonates. *Clin Perinatol*. 2023;50(4):793–803.